Overexpression of ICT1 has been reported in many types of malignancies such as glioblastoma (Xie et al., 2015), diffuse large B cell lymphoma (Xie et al., 2017), colorectal cancer (Lao et al., 2016) prostate cancer (Wang et al., 2015), breast cancer (Chen et al., 2017; Peng et al., 2018), hepatocellular carcinoma (Chang et al., 2017), leukemia (Li et al., 2018), lung cancer (Huang et al., 2014; Wang et al., 2017a) and osteosarcoma (Pan et al., 2021). Here, MRPL58 is linked to lung cancer.